Cargando…
COVID-19 vaccination in adults with inflammatory bowel disease
Patients with inflammatory bowel disease (IBD) are not at increased risk of SARS-CoV-2 infection compared to the general population, and most are not at increased risk for severe disease. COVID-19 is nonetheless common, and vaccination is critical. Four safe and efficacious vaccines are now availabl...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203854/ https://www.ncbi.nlm.nih.gov/pubmed/37234702 http://dx.doi.org/10.1177/17562848231173130 |
_version_ | 1785045720304189440 |
---|---|
author | Lutz, Megan Lazarus, Sarah Caldera, Freddy |
author_facet | Lutz, Megan Lazarus, Sarah Caldera, Freddy |
author_sort | Lutz, Megan |
collection | PubMed |
description | Patients with inflammatory bowel disease (IBD) are not at increased risk of SARS-CoV-2 infection compared to the general population, and most are not at increased risk for severe disease. COVID-19 is nonetheless common, and vaccination is critical. Four safe and efficacious vaccines are now available for the prevention of COVID-19, with most data available for mRNA vaccines. Patients with IBD have a robust humoral response to vaccination with rates of seroconversion exceeding 95% following a two-dose mRNA vaccine series and 99% following a three-dose mRNA series, although those on certain therapies including anti-tumor necrosis factor α agents may have lower antibody concentrations and waning of antibodies over time. Additionally, rates of cell-mediated immune response, even in those patients with IBD who did not have evidence of humoral immunity, are high. Vaccines are safe and have not been associated with flares in disease activity. Gastroenterology providers should take an active role in ensuring patients with IBD are appropriately vaccinated against COVID-19. |
format | Online Article Text |
id | pubmed-10203854 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-102038542023-05-25 COVID-19 vaccination in adults with inflammatory bowel disease Lutz, Megan Lazarus, Sarah Caldera, Freddy Therap Adv Gastroenterol The Impact of COVID-19 in Gastrointestinal Diseases Patients with inflammatory bowel disease (IBD) are not at increased risk of SARS-CoV-2 infection compared to the general population, and most are not at increased risk for severe disease. COVID-19 is nonetheless common, and vaccination is critical. Four safe and efficacious vaccines are now available for the prevention of COVID-19, with most data available for mRNA vaccines. Patients with IBD have a robust humoral response to vaccination with rates of seroconversion exceeding 95% following a two-dose mRNA vaccine series and 99% following a three-dose mRNA series, although those on certain therapies including anti-tumor necrosis factor α agents may have lower antibody concentrations and waning of antibodies over time. Additionally, rates of cell-mediated immune response, even in those patients with IBD who did not have evidence of humoral immunity, are high. Vaccines are safe and have not been associated with flares in disease activity. Gastroenterology providers should take an active role in ensuring patients with IBD are appropriately vaccinated against COVID-19. SAGE Publications 2023-05-22 /pmc/articles/PMC10203854/ /pubmed/37234702 http://dx.doi.org/10.1177/17562848231173130 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | The Impact of COVID-19 in Gastrointestinal Diseases Lutz, Megan Lazarus, Sarah Caldera, Freddy COVID-19 vaccination in adults with inflammatory bowel disease |
title | COVID-19 vaccination in adults with inflammatory bowel disease |
title_full | COVID-19 vaccination in adults with inflammatory bowel disease |
title_fullStr | COVID-19 vaccination in adults with inflammatory bowel disease |
title_full_unstemmed | COVID-19 vaccination in adults with inflammatory bowel disease |
title_short | COVID-19 vaccination in adults with inflammatory bowel disease |
title_sort | covid-19 vaccination in adults with inflammatory bowel disease |
topic | The Impact of COVID-19 in Gastrointestinal Diseases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203854/ https://www.ncbi.nlm.nih.gov/pubmed/37234702 http://dx.doi.org/10.1177/17562848231173130 |
work_keys_str_mv | AT lutzmegan covid19vaccinationinadultswithinflammatoryboweldisease AT lazarussarah covid19vaccinationinadultswithinflammatoryboweldisease AT calderafreddy covid19vaccinationinadultswithinflammatoryboweldisease |